Repligen Corporation Acquires ARTeSYN Biosolutions for $200M

Artis BioSolutions Acquires Landmark Bio

April 2, 2025

Biotechnology

Artis BioSolutions, a newly launched CDMO backed by Oak HC/FT, has acquired Landmark Bio to expand capabilities for the development and manufacturing of cell and gene therapies. Landmark Bio will continue to operate as a distinct entity from its Watertown, Massachusetts headquarters while leveraging Artis' funding and platform to scale process development, GMP manufacturing, and commercialization support.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Biogen Acquires Reata Pharmaceuticals

July 28, 2023

Biotechnology

Biogen Inc. agreed to acquire Reata Pharmaceuticals, Inc. for $172.50 per share in cash, representing an enterprise value of approximately $7.3 billion. The acquisition adds Reata's FDA-approved SKYCLARYS (omaveloxolone) for Friedreich's ataxia to Biogen's rare disease portfolio and is expected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025; the transaction was anticipated to close in Q4 2023.

Sartorius Stedim Biotech Acquires Polyplus

April 13, 2023

Biotechnology

Sartorius Stedim Biotech agreed to acquire Strasbourg-based Polyplus (Polyplus‑transfection S.A.) for €2.4 billion, pending customary regulatory approvals. The transaction buys the business from private equity backers including ARCHIMED and Warburg Pincus and strengthens Sartorius’s cell & gene therapy reagent and upstream bioprocessing portfolio.

Biosynth Carbosynth Acquires Aalto Bio Reagents

May 26, 2022

Biotechnology

Biosynth Carbosynth, a Swiss life‑sciences supplier, has acquired Aalto Bio Reagents, a Dublin‑based developer and provider of biological materials for in‑vitro diagnostics (IVD) and vaccine development. The deal strengthens Biosynth’s IVD and vaccine product portfolio and expands its capabilities to serve diagnostics and vaccine development customers worldwide.

PerkinElmer Acquires BioLegend for Approximately $5.25 Billion

July 26, 2021

Biotechnology

PerkinElmer, Inc. agreed to acquire BioLegend, a leading developer of antibodies and life-science reagents, for approximately $5.25 billion in cash and stock. The acquisition expands PerkinElmer's life-science franchise into high-growth areas such as biologics, cell and gene therapy, and proteogenomics, and is expected to be accretive to earnings.